Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology
Reference34 articles.
1. Pacella E, Pacella F, La Torre G, Impallara D, Malarska K, Brillante C, Turchetti P, De Giusti M (2012) Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment. Clin Ter 163(6):e413–e422
2. Casparis H, Wolfensberger TJ, Becker M, Eich G, Graf N, Ambresin A, Mantel I, Michels S (2014) Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. (Retina Philadelphia, Pa) 34(1):12–17. https://doi.org/10.1097/IAE.0b013e31829f74b0
3. Freiberg FJ, Brynskov T, Munk MR, Sørensen TL, Wolf S, Wirth MA, Becker M, Michels S (2017) Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina (Philadelphia, Pa) 37(12):2341–2346. https://doi.org/10.1097/IAE.0000000000001488
4. Pacella F, Agostinelli E, Carlesimo SC, Nebbioso M, Secondi R, Forastiere M, Pacella E (2016) Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. J Med Case Reports 10(1):282. https://doi.org/10.1186/s13256-016-1077-2
5. Pacella F, Pacella E, Trovato Battagliola E, Malvasi M, Scalinci SZ, Turchetti P, Salducci M, Lucchino L, & Arrico L (2021). Efficacy and safety of intravitreal fluocinolone acetonide microimplant (ILUVIEN®) in patients with chronic diabetic macular edema: 1 year follow-up. European journal of ophthalmology, 11206721211020203. Advance online publication. https://doi.org/10.1177/11206721211020203